Didanosine contraindications: Difference between revisions
Ahmed Zaghw (talk | contribs) No edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 9: | Line 9: | ||
===Allopurinol=== | ===Allopurinol=== | ||
Coadministration of didanosine and allopurinol is contraindicated because systemic exposures of didanosine are increased, which may increase didanosine-associated toxicity. | Coadministration of didanosine and [[allopurinol]] is contraindicated because systemic exposures of didanosine are increased, which may increase didanosine-associated toxicity. | ||
===Ribavirin=== | ===Ribavirin=== | ||
Coadministration of didanosine and ribavirin is contraindicated because exposures of the active metabolite of didanosine (dideoxyadenosine 5′-triphosphate) are increased. Fatal hepatic failure, as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis have been reported in patients receiving both didanosine and ribavirin.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VIDEX (DIDANOSINE) POWDER, FOR SOLUTION [BRISTOL-MYERS SQUIBB COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d4401ca0-98ae-af38-84c7-2f615d0706b9#nlm34089-3| publisher = | date = | accessdate = 1 January 2014 }}</ref> | Coadministration of didanosine and [[ribavirin]] is contraindicated because exposures of the active metabolite of didanosine (dideoxyadenosine 5′-triphosphate) are increased. Fatal [[hepatic failure]], as well as [[peripheral neuropathy]], [[pancreatitis]], and symptomatic hyperlactatemia/[[lactic acidosis]] have been reported in patients receiving both didanosine and ribavirin.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VIDEX (DIDANOSINE) POWDER, FOR SOLUTION [BRISTOL-MYERS SQUIBB COMPANY] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d4401ca0-98ae-af38-84c7-2f615d0706b9#nlm34089-3| publisher = | date = | accessdate = 1 January 2014 }}</ref> | ||
==References== | ==References== | ||
Latest revision as of 05:46, 5 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Contraindications
These recommendations are based on either drug interaction studies or observed clinical toxicities.
Allopurinol
Coadministration of didanosine and allopurinol is contraindicated because systemic exposures of didanosine are increased, which may increase didanosine-associated toxicity.
Ribavirin
Coadministration of didanosine and ribavirin is contraindicated because exposures of the active metabolite of didanosine (dideoxyadenosine 5′-triphosphate) are increased. Fatal hepatic failure, as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis have been reported in patients receiving both didanosine and ribavirin.[1]
References
- ↑ "VIDEX (DIDANOSINE) POWDER, FOR SOLUTION [BRISTOL-MYERS SQUIBB COMPANY]". Retrieved 1 January 2014.
Adapted from the FDA Package Insert.